Efficacy and safety of SOBERANA 02, a COVID-19 conjugate vaccine in heterologous three-dose combination

M. Eugenia Toledo-Romani, M. Garcia-Carmenate, C. Valenzuela Silva, W. Baldoquin-Rodriguez, M. Martínez Pérez, M. C. Rodríguez Gonzalez, B. Paredes Moreno, I. C. Mendoza Hernández, R. González-Mujica Romero, O. Samón Tabio, P. M. Velazco Villares, J. P. Bacallao Castillo, E. Licea Martín, M. Rodríguez Ortega, N. L. Herrera Marrero, E. Caballero Gonzalez, L. I. Egües Torres, R. Duarte González, S. García Blanco, S. Pérez Cabrera, S. Huete Ferreira, K. Idalmis Cisnero, O. Fonte Galindo, D. Meliá Pérez, I. Rojas Remedios, S. Fernandez Castillo, Y. Climent Ruiz, Y. Valdes-Balbin, D. Garcia-Rivera, V. Verez Bencomo, the SOBERANA Phase 3 team
doi: https://doi.org/10.1101/2021.10.31.21265703

Article Information

doi 
https://doi.org/10.1101/2021.10.31.21265703
History 
  • November 6, 2021.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. M. Eugenia Toledo-Romani2,
  2. M. Garcia-Carmenate3,
  3. C. Valenzuela Silva4,
  4. W. Baldoquin-Rodriguez2,
  5. M. Martínez Pérez1,
  6. M. C. Rodríguez Gonzalez1,
  7. B. Paredes Moreno1,
  8. I. C. Mendoza Hernández5,
  9. R. González-Mujica Romero1,
  10. O. Samón Tabio6,
  11. P. M. Velazco Villares7,
  12. J. P. Bacallao Castillo7,
  13. E. Licea Martín1,
  14. M. Rodríguez Ortega2,
  15. N. L. Herrera Marrero2,
  16. E. Caballero Gonzalez1,
  17. L. I. Egües Torres3,
  18. R. Duarte González3,
  19. S. García Blanco3,
  20. S. Pérez Cabrera3,
  21. S. Huete Ferreira3,
  22. K. Idalmis Cisnero3,
  23. O. Fonte Galindo3,
  24. D. Meliá Pérez3,
  25. I. Rojas Remedios3,
  26. S. Fernandez Castillo1,
  27. Y. Climent Ruiz1,
  28. Y. Valdes-Balbin1,
  29. D. Garcia-Rivera1,
  30. V. Verez Bencomo1,*,
  31. the SOBERANA Phase 3 team
  1. 1Finlay Vaccine Institute, Havana
  2. 2Pedro Kourí Tropical Medicine Institute, Havana
  3. 3Havana Province Hygiene and Epidemiology Center
  4. 4Cybernetics, Mathematics and Physics Institute, Havana
  5. 5National Clinical Trials Coordinating Center, Havana
  6. 6José Antonio Echevarría Technological University, Havana
  7. 7UCT Geocuba Research and Consulting, Havana
  1. ↵* Corresponding author; email: vicente.verez{at}finlay.edu.cu
Back to top
Posted November 06, 2021.
Download PDF
Data/Code
Email
Efficacy and safety of SOBERANA 02, a COVID-19 conjugate vaccine in heterologous three-dose combination
M. Eugenia Toledo-Romani, M. Garcia-Carmenate, C. Valenzuela Silva, W. Baldoquin-Rodriguez, M. Martínez Pérez, M. C. Rodríguez Gonzalez, B. Paredes Moreno, I. C. Mendoza Hernández, R. González-Mujica Romero, O. Samón Tabio, P. M. Velazco Villares, J. P. Bacallao Castillo, E. Licea Martín, M. Rodríguez Ortega, N. L. Herrera Marrero, E. Caballero Gonzalez, L. I. Egües Torres, R. Duarte González, S. García Blanco, S. Pérez Cabrera, S. Huete Ferreira, K. Idalmis Cisnero, O. Fonte Galindo, D. Meliá Pérez, I. Rojas Remedios, S. Fernandez Castillo, Y. Climent Ruiz, Y. Valdes-Balbin, D. Garcia-Rivera, V. Verez Bencomo, the SOBERANA Phase 3 team
medRxiv 2021.10.31.21265703; doi: https://doi.org/10.1101/2021.10.31.21265703
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area